

MEDIMMUNE INC /DE
Form 8-K
July 22, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report

July 22, 2004

MedImmune, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

0-19131
(Commission File No.)

52-1555759
(I.R.S. Employer Identification No.)

One MedImmune Way, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 398-0000

Item 5. Other Events and Regulation FD Disclosure.

On July 22, 2004, MedImmune, Inc. (the Company) issued a press release announcing the Company's results for the three-month and nine-month periods ended June 30, 2004 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of the Company's press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the paragraph entitled "Guidance for the Quarter Ending September 30, 2004," is incorporated by reference under this Item.

Item 7. Financial Statements and

| Exhibit No. | Description |
|-------------|-------------|
|-------------|-------------|

| | |
|------|---|
| 99.1 | Press Release, dated July 22, 2004, "MedImmune Reports 2004 Second Quarter and Six-Month Results" |
|------|---|

Item 12. Results of Operations and Financial Condition.

This press release is hereby furnished in its entirety pursuant to Item 12. This information is not deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any registration statements filed under the Securities Act of 1933 or any report filed under the Securities Exchange Act of 1934, except as described above under the caption "Item 5. Other Events and Regulation FD Disclosure."

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDIMMUNE, INC.

BY: /s/ Lota S. Zoth

Lota S. Zoth
Senior Vice President and Chief Financial Officer and Acting Controller

Dated: July 22, 2004